“Advanced Pancreatic Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Pancreatic Cancer Market.
The Advanced Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Pancreatic Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Advanced Pancreatic Cancer treatment therapies with a considerable amount of success over the years.
Advanced Pancreatic Cancer companies working in the treatment market are Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others, are developing therapies for the Advanced Pancreatic Cancer treatment
Emerging Advanced Pancreatic Cancer therapies in the different phases of clinical trials are- IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others are expected to have a significant impact on the Advanced Pancreatic Cancer market in the coming years.
In March 2025, Swedish immunotherapy firm Anocca received regulatory approval in four European countries to conduct its Phase I/II VIDAR-1 clinical trial. This study will target patients with KRAS-positive advanced pancreatic cancer and will start by testing ANOC-001, Anocca’s main product designed to target the KRAS G12V mutation.
In March 2025, Anocca AB, a prominent T-cell immunotherapy firm, received approval for its Clinical Trial Application (CTA) from regulatory bodies in four European countries under the EU’s unified framework, with Germany serving as the reference country. The trial, VIDAR-1, is a Phase I/II multi-product umbrella study focused on patients with mutated KRAS-positive advanced pancreatic cancer. VIDAR-1 will evaluate several products, beginning with Anocca’s lead candidate ANOC-001, which targets the mutant KRAS G12V. ANOC-001 is a novel innovation developed through Anocca’s platform and will be produced at the company’s in-house cGMP facility.
In December 2024, Novocure (NASDAQ: NVCR) announced that the pivotal Phase 3 PANOVA-3 trial achieved its primary goal, showing a statistically significant increase in median overall survival (mOS) compared to the control group. The PANOVA-3 study assessed Tumor Treating Fields (TTFields) therapy used alongside gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.
In November 2024, Anocca AB, a prominent company specializing in T-cell receptor-engineered T-cell (TCR-T) therapies, has submitted its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for VIDAR-1, a Phase I/II multi-asset umbrella trial. The VIDAR-1 program will commence with ANOC-001, a therapy targeting mutant KRAS G12V in patients with advanced Advanced Pancreatic Cancer. Pending CTA approval, Anocca plans to launch the trial in the second quarter of 2025. ANOC-001 is the flagship product from Anocca’s extensive preclinical pipeline of TCR-T cell therapies.
Advanced Pancreatic Cancer Overview
Advanced Pancreatic Cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.
Get a Free Sample PDF Report to know more about Advanced Pancreatic Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-pancreatic-cancer-pipeline-insight
Emerging Advanced Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:
IMC-R117C: Immunocore
CT7001: Carrick Therapeutics
DK210: DEKA Biosciences
CMG901: Keymed Biosciences
AB011: CARsgen Therapeutics
Rintatolimod: AIM ImmunoTech Inc.
RXC004: Redx Pharma Plc
RAIN-32: Rain Oncology
Pamrevlumab: FibroGen
NIS793: Novartis AG
Pembrolizumab: Merck & Co
Lynparza: AstraZeneca
Advanced Pancreatic Cancer Route of Administration
Advanced Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Advanced Pancreatic Cancer Molecule Type
Advanced Pancreatic Cancer Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Advanced Pancreatic Cancer Pipeline Therapeutics Assessment
Advanced Pancreatic Cancer Assessment by Product Type
Advanced Pancreatic Cancer By Stage and Product Type
Advanced Pancreatic Cancer Assessment by Route of Administration
Advanced Pancreatic Cancer By Stage and Route of Administration
Advanced Pancreatic Cancer Assessment by Molecule Type
Advanced Pancreatic Cancer by Stage and Molecule Type
DelveInsight’s Advanced Pancreatic Cancer Report covers around products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Advanced Pancreatic Cancer product details are provided in the report. Download the Advanced Pancreatic Cancer pipeline report to learn more about the emerging Advanced Pancreatic Cancer therapies
Some of the key companies in the Advanced Pancreatic Cancer Therapeutics Market include:
Key companies developing therapies for Advanced Pancreatic Cancer are – AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.
Advanced Pancreatic Cancer Pipeline Analysis:
The Advanced Pancreatic Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Pancreatic Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Pancreatic Cancer Treatment.
Advanced Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Advanced Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Pancreatic Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Pancreatic Cancer drugs and therapies
Advanced Pancreatic Cancer Pipeline Market Drivers
Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Advanced Pancreatic Cancer Market.
Advanced Pancreatic Cancer Pipeline Market Barriers
However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in Advanced Pancreatic Cancer and other factors are creating obstacles in the Advanced Pancreatic Cancer Market growth.
Scope of Advanced Pancreatic Cancer Pipeline Drug Insight
Coverage: Global
Key Advanced Pancreatic Cancer Companies: Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others
Key Advanced Pancreatic Cancer Therapies: IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others
Advanced Pancreatic Cancer Therapeutic Assessment: Advanced Pancreatic Cancer current marketed and Advanced Pancreatic Cancer emerging therapies
Advanced Pancreatic Cancer Market Dynamics: Advanced Pancreatic Cancer market drivers and Advanced Pancreatic Cancer market barriers
Request for Sample PDF Report for Advanced Pancreatic Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Advanced Pancreatic Cancer Report Introduction
2. Advanced Pancreatic Cancer Executive Summary
3. Advanced Pancreatic Cancer Overview
4. Advanced Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment
5. Advanced Pancreatic Cancer Pipeline Therapeutics
6. Advanced Pancreatic Cancer Late Stage Products (Phase II/III)
7. Advanced Pancreatic Cancer Mid Stage Products (Phase II)
8. Advanced Pancreatic Cancer Early Stage Products (Phase I)
9. Advanced Pancreatic Cancer Preclinical Stage Products
10. Advanced Pancreatic Cancer Therapeutics Assessment
11. Advanced Pancreatic Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Pancreatic Cancer Key Companies
14. Advanced Pancreatic Cancer Key Products
15. Advanced Pancreatic Cancer Unmet Needs
16 . Advanced Pancreatic Cancer Market Drivers and Barriers
17. Advanced Pancreatic Cancer Future Perspectives and Conclusion
18. Advanced Pancreatic Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
